MODERNA INC (1MRNA.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1MRNA - US60770K1079 - Common Stock
35.98 EUR
+1.47 (+4.27%)
Taking everything into account, 1MRNA scores 3 out of 10 in our fundamental rating. 1MRNA was compared to 86 industry peers in the Biotechnology industry. While 1MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, 1MRNA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- 1MRNA had negative earnings in the past year.
- In the past year 1MRNA has reported a negative cash flow from operations.
- The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: 1MRNA reported negative operating cash flow in multiple years.
1.2 Ratios
- 1MRNA's Return On Assets of -25.68% is in line compared to the rest of the industry. 1MRNA outperforms 55.81% of its industry peers.
- With a decent Return On Equity value of -33.40%, 1MRNA is doing good in the industry, outperforming 65.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| ROIC | N/A |
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 63.49%, 1MRNA is in the better half of the industry, outperforming 60.47% of the companies in the same industry.
- In the last couple of years the Gross Margin of 1MRNA has declined.
- 1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- 1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, 1MRNA has more shares outstanding
- 1MRNA has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, 1MRNA has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.24 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
- The Altman-Z score of 1MRNA (4.24) is better than 75.58% of its industry peers.
- 1MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- 1MRNA's Debt to Equity ratio of 0.00 is amongst the best of the industry. 1MRNA outperforms 89.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.24 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
- 1MRNA has a Current Ratio of 3.93. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.93, 1MRNA is in the better half of the industry, outperforming 75.58% of the companies in the same industry.
- 1MRNA has a Quick Ratio of 3.73. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
- 1MRNA has a Quick ratio of 3.73. This is in the better half of the industry: 1MRNA outperforms 75.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.73 |
3. Growth
3.1 Past
- The earnings per share for 1MRNA have decreased strongly by -38.66% in the last year.
- Looking at the last year, 1MRNA shows a very negative growth in Revenue. The Revenue has decreased by -56.07% in the last year.
- Measured over the past years, 1MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%
3.2 Future
- Based on estimates for the next years, 1MRNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.39% on average per year.
- 1MRNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.92% yearly.
EPS Next Y11.55%
EPS Next 2Y10.72%
EPS Next 3Y13.31%
EPS Next 5Y16.39%
Revenue Next Year-41.52%
Revenue Next 2Y-22.32%
Revenue Next 3Y-11.6%
Revenue Next 5Y10.92%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
- Also next year 1MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as 1MRNA's earnings are expected to grow with 13.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.72%
EPS Next 3Y13.31%
5. Dividend
5.1 Amount
- 1MRNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIT:1MRNA (1/16/2026, 7:00:00 PM)
35.98
+1.47 (+4.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners71.72%
Inst Owner ChangeN/A
Ins Owners2.73%
Ins Owner ChangeN/A
Market Cap14.06B
Revenue(TTM)2.23B
Net Income(TTM)-3.12B
Analysts56
Price Target32.13 (-10.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.94%
Min EPS beat(2)29.6%
Max EPS beat(2)76.27%
EPS beat(4)3
Avg EPS beat(4)30.21%
Min EPS beat(4)-6.26%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)49.68%
EPS beat(12)9
Avg EPS beat(12)9.25%
EPS beat(16)12
Avg EPS beat(16)10.78%
Revenue beat(2)2
Avg Revenue beat(2)17.81%
Min Revenue beat(2)12.36%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)8.94%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.87%
Revenue beat(12)10
Avg Revenue beat(12)27.21%
Revenue beat(16)13
Avg Revenue beat(16)22.97%
PT rev (1m)-2.24%
PT rev (3m)-19.26%
EPS NQ rev (1m)0.24%
EPS NQ rev (3m)6.82%
EPS NY rev (1m)0.09%
EPS NY rev (3m)17.74%
Revenue NQ rev (1m)-4.9%
Revenue NQ rev (3m)-17.12%
Revenue NY rev (1m)-0.93%
Revenue NY rev (3m)-2.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.75 | ||
| P/tB | 1.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.95
EYN/A
EPS(NY)-6.18
Fwd EYN/A
FCF(TTM)-5.87
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS4.92
BVpS20.56
TBVpS20.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.49% | ||
| FCFM | N/A |
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 329.33% | ||
| Cap/Sales | 30.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.73 | ||
| Altman-Z | 4.24 |
F-Score2
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
EPS Next Y11.55%
EPS Next 2Y10.72%
EPS Next 3Y13.31%
EPS Next 5Y16.39%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%
Revenue Next Year-41.52%
Revenue Next 2Y-22.32%
Revenue Next 3Y-11.6%
Revenue Next 5Y10.92%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.1%
EBIT Next 3Y15.77%
EBIT Next 5Y17.94%
FCF growth 1Y-0.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A
MODERNA INC / 1MRNA.MI FAQ
Can you provide the ChartMill fundamental rating for MODERNA INC?
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI.
What is the valuation status for 1MRNA stock?
ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (1MRNA.MI). This can be considered as Overvalued.
Can you provide the profitability details for MODERNA INC?
MODERNA INC (1MRNA.MI) has a profitability rating of 2 / 10.
How financially healthy is MODERNA INC?
The financial health rating of MODERNA INC (1MRNA.MI) is 6 / 10.
What is the expected EPS growth for MODERNA INC (1MRNA.MI) stock?
The Earnings per Share (EPS) of MODERNA INC (1MRNA.MI) is expected to grow by 11.55% in the next year.